NCT07001709Phase 4Recruiting
Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)
Deventer Ziekenhuis · Deventer Ziekenhuis, Deventer, Overijssel
Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.
Eligibility: 18 Years to · Male · * Diagnosed prostate cancer; * Males aged 18 years or older; * Treated with abiraterone 1000 mg once daily for at least 10 days (abiraterone arm). * Not treated with abiraterone 1000 mg once daily for at least 10 days (control arm).